Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). The prominent use of generically available drugs (e.g., selective serotonin reuptake inhibitors) as early-line treatments contributes to the market access challenges that branded therapies face when entering this market. Of note, brand-only drugs (e.g., Lundbeck / Takeda’s Trintellix, Lundbeck / Otsuka Pharmaceutical’s Rexulti) largely compete for use in treatment-resistant depression (TRD) patients. Nevertheless, given the high unmet need for effective treatments for inadequate responders to early-line therapies and treatment-resistant patients, newer-to-market drugs (e.g., Janssen’s Spravato, Axsome Therapeutics’ Auvelity) and late-phase emerging drugs (e.g., COMPASS Pathways’ COMP360 psilocybin) seem promising. Although the expanding presence of generic drugs has given payers more leverage to control drug treatment costs in MDD, understanding the current and expected influence of clinical metrics and value-for-dollar on market access and medical practice is key for marketers and developers of new therapies for MDD.
Geography: United States
Primary research: Survey of 101 U.S. psychiatrists, survey of 30 U.S. MCO PDs / MDs
Fingertip formulary: Formulary coverage and restrictions data for MDD therapies by commercial plans covering approximately 169.5 million lives nationally.
Key drugs covered: Trintellix, Spravato, Auvelity, Rexulti, Vraylar, Caplyta, COMP360 psilocybin, zuranolone
Reimbursement and contracting.
Access and prescribing.
Opportunities and challenges for emerging therapies.
Disease-specific special topic: Treatment-Resistant Depression.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.